These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 31119864)

  • 21. Ten years of proteomics in multiple sclerosis.
    Farias AS; Pradella F; Schmitt A; Santos LM; Martins-de-Souza D
    Proteomics; 2014 Mar; 14(4-5):467-80. PubMed ID: 24339438
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of Novel Biomarkers for Diagnosing and Predicting the Progression of Multiple Sclerosis Using TMT-Based Quantitative Proteomics.
    Shi Y; Ding Y; Li G; Wang L; Osman RA; Sun J; Qian L; Zheng G; Zhang G
    Front Immunol; 2021; 12():700031. PubMed ID: 34489947
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proteome analysis of post-transplantation recovery mechanisms of an EAE model of multiple sclerosis treated with embryonic stem cell-derived neural precursors.
    Fazeli AS; Nasrabadi D; Pouya A; Mirshavaladi S; Sanati MH; Baharvand H; Salekdeh GH
    J Proteomics; 2013 Dec; 94():437-50. PubMed ID: 23791935
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted mass spectrometry approaches for protein biomarker verification.
    Meng Z; Veenstra TD
    J Proteomics; 2011 Nov; 74(12):2650-9. PubMed ID: 21540133
    [TBL] [Abstract][Full Text] [Related]  

  • 25. B cells in multiple sclerosis.
    Wekerle H
    Autoimmunity; 2017 Feb; 50(1):57-60. PubMed ID: 28166681
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Implementation of CE-MS-identified proteome-based biomarker panels in drug development and patient management.
    Stepczynska A; Schanstra JP; Mischak H
    Bioanalysis; 2016; 8(5):439-55. PubMed ID: 26891752
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Insights into the human brain proteome: Disclosing the biological meaning of protein networks in cerebrospinal fluid.
    Bastos P; Ferreira R; Manadas B; Moreira PI; Vitorino R
    Crit Rev Clin Lab Sci; 2017 May; 54(3):185-204. PubMed ID: 28393582
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prediction of combination therapies based on topological modeling of the immune signaling network in multiple sclerosis.
    Bernardo-Faura M; Rinas M; Wirbel J; Pertsovskaya I; Pliaka V; Messinis DE; Vila G; Sakellaropoulos T; Faigle W; Stridh P; Behrens JR; Olsson T; Martin R; Paul F; Alexopoulos LG; Villoslada P; Saez-Rodriguez J
    Genome Med; 2021 Jul; 13(1):117. PubMed ID: 34271980
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Candidate proteomic biomarkers for non-alcoholic fatty liver disease (steatosis and non-alcoholic steatohepatitis) discovered with mass-spectrometry: a systematic review.
    Lădaru A; Bălănescu P; Stan M; Codreanu I; Anca IA
    Biomarkers; 2016; 21(2):102-14. PubMed ID: 26632636
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Revisiting biomarker discovery by plasma proteomics.
    Geyer PE; Holdt LM; Teupser D; Mann M
    Mol Syst Biol; 2017 Sep; 13(9):942. PubMed ID: 28951502
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipids and lipid-reactive antibodies as biomarkers for multiple sclerosis.
    Quintana FJ; Yeste A; Weiner HL; Covacu R
    J Neuroimmunol; 2012 Jul; 248(1-2):53-7. PubMed ID: 22579051
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biomarkers: mining the biofluid proteome.
    Veenstra TD; Conrads TP; Hood BL; Avellino AM; Ellenbogen RG; Morrison RS
    Mol Cell Proteomics; 2005 Apr; 4(4):409-18. PubMed ID: 15684407
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An emerging potential of metabolomics in multiple sclerosis: a comprehensive overview.
    Zahoor I; Rui B; Khan J; Datta I; Giri S
    Cell Mol Life Sci; 2021 Apr; 78(7):3181-3203. PubMed ID: 33449145
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of novel disease-specific and membrane-associated candidate markers in a mouse model of multiple sclerosis.
    Dagley LF; Croft NP; Isserlin R; Olsen JB; Fong V; Emili A; Purcell AW
    Mol Cell Proteomics; 2014 Mar; 13(3):679-700. PubMed ID: 24361864
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuroinflammation: From Molecular Basis to Therapy.
    Zanella I
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mass Spectrometric-Based Proteomics for Biomarker Discovery in Osteosarcoma: Current Status and Future Direction.
    Sirikaew N; Pruksakorn D; Chaiyawat P; Chutipongtanate S
    Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077137
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low-level laser therapy ameliorates disease progression in a mouse model of multiple sclerosis.
    Gonçalves ED; Souza PS; Lieberknecht V; Fidelis GS; Barbosa RI; Silveira PC; de Pinho RA; Dutra RC
    Autoimmunity; 2016; 49(2):132-42. PubMed ID: 26703077
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early response index: a statistic to discover potential early stage disease biomarkers.
    Salekin S; Bari MG; Raphael I; Forsthuber TG; Zhang JM
    BMC Bioinformatics; 2017 Jun; 18(1):313. PubMed ID: 28645323
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mass spectrometry-based proteomics for pre-eclampsia and preterm birth.
    Law KP; Han TL; Tong C; Baker PN
    Int J Mol Sci; 2015 May; 16(5):10952-85. PubMed ID: 26006232
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiple sclerosis biomarkers: Helping the diagnosis?
    Thouvenot E
    Rev Neurol (Paris); 2018 Jun; 174(6):364-371. PubMed ID: 29784249
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.